Evidence map›Paper›PMID 28271456›Full record

ArticleEating and weight disorders : EWD2017

Niclosamide as an anti-obesity drug: an experimental study.

Ali I Al-Gareeb, Khalid D Aljubory, Hayder M Alkuraishy

Abstract read
PubMed Publisher
In one paragraph

Article in Eating and weight disorders : EWD, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Repurposing niclosamide to mitigate inflammaging: a review of multi-target mechanisms in cellular senescence and age-related decline.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Niclosamide-A promising treatment for COVID-19.British journal of pharmacology · 2022
    Review
  7. Review
  8. Niclosamide for Covid-19: bridging the gap.Molecular biology reports · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Effects of rosuvastatin on metabolic profile: Versatility of dose-dependent effect.Journal of advanced pharmaceutical technology & research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ali I Al-GareebClinical Pharmacology and Therapeutics, Department of Clinical Pharmacology and Therapeutics, College of Medicine, Al-Mustansiriya University, P.O. Box 14132, Baghdad, Iraq. dr.alialgareeb78@yahoo.com.ORCID http://orcid.org/0000-0001-8284-8897
Khalid D AljuboryClinical Pharmacist at Ministry of Health, Baghdad, Iraq.
Hayder M AlkuraishyClinical Pharmacology and Therapeutics, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq.
Mustansiriyah University · IQMinistry of Health · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNiclosamide is a well-known anthelminthic drug that exert its effects at least in part through induction of mitochondrial uncoupling. The cycling of mitochondrial proton plays an essential role in regulation of basal metabolic rate, so modulation of mitochondrial uncoupling may be helpful approach to fight obesity.

objectiveTo assess the anti-obesity effects of niclosamide on mice with induced obesity. MATERIALS AND

methodsThirty male Albino mice, 8-10 weeks old, were divided randomly and equally in to three groups; Group 1 fed with standard diet, whereas both Groups 2 and 3 were fed with high fat diet (HFD). At 10 weeks, the studied groups continue in the same type of diet as before for another 4 weeks, but additionally both of Group1 and 2 received placebo treatment as normal control and high fat diet control respectively, whereas Group 3 received oral niclosamide (140 mg/kg/day) as treatment group. The anti-obesity effects of niclosamide were evaluated by testing its effects on food intake, bodyweight, glycemic indices, and lipid profile.

resultIt was found that administration of niclosamide 140 mg/kg/day to HFD fed mice (Group3) for 4 weeks resulted in significant (P < 0.05) decline in the food intake and bodyweight of this group as compared with HFD control. Furthermore, niclosamide also resulted in significant (P < 0.05) lowering of the fasting blood glucose, fasting plasma insulin and improve insulin resistance. Likewise, niclosamide ameliorates the harmful effects of HFD on lipid profile by significant lowering of cholesterol, triglycerides, and LDL (P < 0.05).

conclusionNiclosamide has promising effects as an anti-obesity drug. It not just lowers bodyweight in mice, but, at the same time, it reverses metabolic disturbance induced by obesity.

Indexed as

AnimalsAnti-Obesity AgentsBlood GlucoseBody WeightCholesterolDiet, High-FatEatingInsulin ResistanceMaleMiceNiclosamideObesityTreatment OutcomeTriglyceridesAnti-Obesity AgentsBlood GlucoseCholesterolNiclosamideTriglyceridesLipid profileMitochondrial uncouplingNiclosamideObesity

Identifiers

PMID28271456
OpenAlexW2592991005

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.